Shares of Black Diamond Therapeutics Inc. (BDTX) are up nearly 40% at $2.34 in premarket trading today, on news of the company entering into a strategic worldwide licensing agreement for its investigational drug BDTX-4933, with Servier, an independent global pharmaceutical group governed by a non-profit foundation.
BDTX-4933, designed to target RAS and RAF alterations in solid tumors, is currently in phase I development.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com